Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive topline results from the clinical study OX640-002. The study evaluated the performance in subjects with and without allergic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback